[Vaccination rate of premature infants at 6 and 24 months of age: a pilot study]

D Pinquier1, C Adde-Michela, D Ploin

  • 1EA4309, Service de Pédiatrie Néonatale et Réanimation, Université de Rouen, CHU Charles-Nicolle, Institut Hospitalo-Universitaire de Recherche Biomédicale, 1 Rue Germont, 76031 Rouen Cedex, France. didier.pinquier@chu-rouen.fr

Insights

Vaccine coverage for premature infants born before 33 weeks gestation is often delayed and incomplete, increasing their risk for preventable diseases. Early, in-hospital vaccination initiation is recommended for these vulnerable infants.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Context:

  • Premature infants born before 33 weeks gestation (VLBW infants) have unique health needs.
  • Vaccine practices for this population are not well-documented.
  • Adherence to the recommended immunization schedule is crucial for preventing infectious diseases.

Purpose:

  • To examine vaccine coverage in premature infants aged 0–24 months.
  • To assess adherence to the French national immunization schedule.
  • To identify gaps in vaccination practices for this high-risk group.

Summary:

  • A prospective study of 87 premature infants revealed delayed vaccine initiation and suboptimal coverage for DTPCoqHib, hepatitis B, and MMR vaccines by 2 years of age.
  • While BCG coverage was high, hepatitis B vaccination remained incomplete in a significant proportion of infants.
  • Vaccination practices did not align with chronological age, leaving infants susceptible to pertussis during the first six months.

Impact:

  • Delayed vaccination increases the window of susceptibility to serious infections like pertussis in premature infants.
  • Current vaccination practices necessitate adjustments to ensure timely and complete immunization.
  • In-hospital vaccination programs and caregiver vaccination are proposed strategies to improve infant immunization rates.
Abstract

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...